RVL Pharmaceuticals

RVL Pharmaceuticals Current Assets

The Current Assets of RVL Pharmaceuticals (RVLPQ) as of Nov 16, 2026 is 56.94 M USD. In the previous year, Current Assets was 62.41 M USD — a change of -8.76% (lower).

Current Assets

56.94 MUSD

YoY

-8.76%

Last updated:

Current Assets of RVL Pharmaceuticals is 2022 56.94 M USD. Current Assets of RVL Pharmaceuticals was 2021 62.41 M USD. It decreases by -8.76% lower compared to the previous year.

The RVL Pharmaceuticals Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2016
94.19 M USD
Jan 1, 2017
115.10 M USD
Jan 1, 2018
172.34 M USD
Jan 1, 2019
172.62 M USD
Jan 1, 2020
196.41 M USD
Jan 1, 2021
62.41 M USD
Jan 1, 2022
56.94 M USD
The RVL Pharmaceuticals Current Assets history
YEARCurrent AssetsYoY
56.94 MUSD-8.76%
62.41 MUSD-68.22%
196.41 MUSD+13.78%
172.62 MUSD+0.16%
172.34 MUSD+49.72%
115.10 MUSD+22.20%
94.19 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

RVL Pharmaceuticals Stock analysis

What does RVL Pharmaceuticals do? Osmotica Pharmaceuticals PLC is a global pharmaceutical company based in Dublin, Ireland. It was founded in 2008 and focuses on the development and marketing of specialized pharmaceutical products for the treatment of neurological and psychiatric disorders, as well as behavioral disorders. The company is divided into three business segments: the Commercial Part, the Branded Part, and the Trident Part. The Commercial Part is responsible for marketing generic pharmaceuticals and other specialty products in the USA and Canada. This includes products such as Venlafaxine ER for the treatment of depression and the Parkinson's medication Apomorphine. The Branded Part is responsible for the development and marketing of its own products. This includes products such as Osmolex ER for the treatment of Parkinson's and akathisia, as well as Ontinua ER for the treatment of fibromyalgia and neuropathies. The Trident Part of the company focuses on the development of novel ophthalmology products and other specialty products for the global market. The company has a strong commitment to clinical research and development, particularly in the development of new products for use in neurology and psychiatry. Osmotica holds a number of patents for its products and has a range of products in various stages of clinical development. The success of Osmotica is based on its business model, which relies on ongoing innovation through research and development, as well as a strong distribution network for its products. Thanks to its broad product portfolio and global presence, the company is well positioned for further growth and the expansion into new markets in the future. Overall, Osmotica Pharmaceuticals PLC is an emerging pharmaceutical company with a strong focus on the development of specialized products for neurological and psychiatric disorders, as well as behavioral disorders. The company has a broad product portfolio and is well positioned for future growth. RVL Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about RVL Pharmaceuticals stock

Current Assets of RVL Pharmaceuticals is 56.94 M USD in 2022.

Current Assets of RVL Pharmaceuticals changed from 62.41 M USD to 56.94 M USD, representing a -8.76% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Assets RVL Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's RVL Pharmaceuticals historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — RVL Pharmaceuticals

All Key Metrics — RVL Pharmaceuticals